Nirland Ltd, a shareholder in Conduit Pharmaceuticals Inc. (CDT), has engaged in a series of stock disposals from October 3, 2024, to October 7, 2024. The transactions involved the sale of 3,808,000 shares of common stock, directly held by the shareholder. The sales occurred in the open market at prices ranging from $0.1026 to $0.1043 per share, resulting in a total market value of approximately $393,438.60. Following these transactions, Nirland Ltd's direct holdings in Conduit Pharmaceuticals have decreased to 6,092,000 shares. The sales are reported to be in progress, indicating that further transactions may occur.

Nirland Ltd, a shareholder in Conduit Pharmaceuticals Inc. (CDT), has engaged in a series of stock disposals from October 3, 2024, to October 7, 2024. The transactions involved the sale of 3,808,000 shares of common stock, directly held by the shareholder. The sales occurred in the open market at prices ranging from $0.1026 to $0.1043 per share, resulting in a total market value of approximately $393,438.60. Following these transactions, Nirland Ltd's direct holdings in Conduit Pharmaceuticals have decreased to 6,092,000 shares. The sales are reported to be in progress, indicating that further transactions may occur.